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a  b  s  t  r  a  c  t
Leukemia  arises  due  to  the  dysregulated  proliferation  of hematopoietic  progenitor  cells.  Errors  in  the
multi-step  commitment  process  result  in  excessive  numbers  of  immature  lymphocytes,  causing  malig-
nant  disease.  Genes  involved  in  the  differentiation  of  lymphocytes  are  often  associated  with  leukemia.
One  such  gene,  Zfp521,  has  been  found  to  cause  B-cell  leukemia  in  mice when  over-expressed.  The  role
of  Zfp521  in B-cell  differentiation,  and  the  mechanisms  by  which  it  leads  to leukemic  transformation,  are
unclear.  In this  study  we  report  that Zfp521  knockdown  causes  apoptosis  in a  B-cell  culture  system  andeywords:
fp521
ax5
yclin D1
fp423
bf1
promotes  down-regulation  of genes  acting  at late  stages  of  B-cell  differentiation.  We  identify  Pax5  and
cyclin  D1  as  Zfp521  target  genes,  and  suggest  that  excessive  B-cell  proliferation  observed  in  mice  with
retroviral  insertions  near  the  Zfp521  gene  is due  to an  up-regulation  of  cyclin  D1  in B-cells.  Overall,  these
results  suggest  links  between  dysregulated  Zfp521  and  B-cell  survival.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
vi3
. Introduction
Leukemia originates due to errors in the hematopoietic differ-
ntiation of stem cells into mature lymphocytes [1]. Lymphocyte
evelopment requires a multi-step process whereby common lym-
hoid progenitors differentiate into B and T lineage-speciﬁc cells
2]. Developmental control of early B lineage cell differentiation
s exerted by a regulatory network of key transcription factors
3,4]. Sequential actions of these transcription factors results in the
ulti-step differentiation of mature B-cells from immature pro-
enitors in the bone marrow [4].
Recombinant inbred (RI) mouse stains are a signiﬁcant resource
or leukemia gene discovery [5]. These mice harbor somatic viral
nsertions that alter the expression of tumor suppressor genes and
roto-oncogenes [5,6]. Sites of proviral insertion that are com-
on  to many animals within a strain or between multiple strains
dentify genomic locations where proto-oncogenes or tumor sup-
ressor genes reside. The RI strain AKXD-27 possessed B-lineage
ymphomas with a common proviral insertion site, designated as
cotropic viral integration site 3 (Evi3) [7]. Within the AKXD-27
train 70% of mice exhibiting pre-B cell and B-cell tumors contained
roviral insertions at the Evi3 locus; no rearrangements at the Evi3
∗ Corresponding author at: Michael Smith Building, Oxford Road, Manchester M13
PT,  UK.
E-mail address: Kathryn.Hentges@manchester.ac.uk (K.E. Hentges).
ttp://dx.doi.org/10.1016/j.leukres.2016.03.013
145-2126/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
locus were found in either T-cell or myeloid tumors [7,8]. The high
frequency of B-lineage lymphoma in mice with a proviral inser-
tion at the Evi3 locus suggests that proviral insertion alters the
expression of genes near the insertion site to promote B-lineage
lymphoma.
Analysis of the genomic region surrounding the Evi3 retrovi-
ral integration site revealed that the virus had inserted upstream
of a previously uncharacterized gene, which encodes a 30-zinc-
ﬁnger protein with predicted DNA-binding and protein interaction
domains [8,9]. This gene was found to be up-regulated in tumors
with retroviral insertions at Evi3, due to the strong viral promot-
ers driving endogenous gene expression [9]. The human ortholog
of this gene, EHZF, was identiﬁed due to its speciﬁc expression
in CD34+ early hematopoietic progenitor stem cells [10]. Due to
its zinc ﬁnger motifs, the gene at the Evi3 insertion site has been
renamed Zfp521 in mice and ZNF521 in humans.
Although studies on the molecular function of Zfp521 have
revealed a role in transcriptional regulation via chromatin remod-
eling [11], its place within the transcriptional network regulating
B-cell differentiation remains unclear. To better understand the role
of Zfp521 in B-lymphocytes, we developed a knockdown system in
the lymphoblast cell line BCL1, which secretes IgD and IgM anti-
bodies [12]. We assayed B-cell gene expression in this system, and
found that certain genes which were up-regulated in B-cell tumors
from AKXD-27 mice with Evi3 retroviral insertions [8] were con-
versely down-regulated in Zfp521 knockdown cells. Knocking down
Zfp521 resulted in decreased cellular viability and increased cel-
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. The Zfp521 BCL1 B-cell knockdown system. A. Zfp521 expression is present in the Pro-B cell line Ba/F3. Ladder = Bioline Hyperladder I, neg = no template control.
B.  Zfp521 expression is signiﬁcantly reduced in BCL1 cells transfected with a speciﬁc shRNA as compared to mock-transfected cells at both 24 h (*p = 0.03; t test) and 48 h
(*p  = 0.006; t test). C. Zfp423 expression is unaffected in cells transfected with Zfp521 shRNA at either 24 h (p = 0.19; t test) or 48 h (p = 0.69; t test). D. The presence of
viable  cells is signiﬁcantly reduced in cultures transfected with Zfp521 shRNA when compared to cells undergoing mock transfection at 3 days and 7 days post-transfection
(*p  < 0.05; t test), or transfection with vector containing no shRNA (negative) or scrambled shRNA sequence. E. The percentage of dead cells at days 3 and 7 post-transfection
as  identiﬁed by trypan blue staining is signiﬁcantly increased in cells transfected with Zfp521 shRNA as compared to cells undergoing mock transfection (*p < 0.05; t test), or
transfection with vector containing no shRNA (negative) or scrambled shRNA sequence. F. The fold-change in the levels of Caspase 3/7 activity in cells transfected with Zfp521
shRNA or control plasmids as compared to mock-transfected cells. A signiﬁcant increase in Caspase 3/7 activity is detected in Zfp521 shRNA transfected cells compared to
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ular apoptosis. Using a cell viability rescue assay, we identiﬁed
yclin D1 as a potential mediator of increased B-cell proliferation
n Zfp521 over-expressing leukemias, and propose a position for
fp521 within the B-cell differentiation transcriptional regulatory
etwork.
. Materials & methods
.1. Cell culture
Mouse lymphoblast cells (BCL1; ATCC® TIB-197) were cul-
ured in RPMI 1640 medium supplemented with 2 mM L-glutamine
Lonza), 0.05 mM 2-mercaptoethanol (Sigma-Aldrich), 15% FBS, 5%
enicillin, 5% streptomycin at 37 ◦C with 5% CO2.
.2. Zfp521 shRNA constructs
shRNA constructs were purchased from OriGene (OriGene Tech-
ologies: SR422637). Four independent Zfp521 shRNA expression
ectors with a CMV-Green Fluorescent Protein (GFP) marker were
ombined at equal concentration for transfection. A vector contain-
ng scrambled Zfp521 shRNA sequence and an empty vector lacking
ny shRNA sequence were used as controls.
.3. Transfection1 g plasmid DNA was transfected into 1 × 105 BCL1 cells with
uGENE HD (Roche) in OptiMEM Media (Sigma). Transfection
fﬁciency was calculated based on the GFP expression for each
ndividual plasmid.2.4. Viability assay
BCL1 were plated in triplicate at a density of 1 × 105 cells per
well in 96-well plate. After 24 h, cells were transfected with shRNA
plasmids or appropriate control plasmids and cultured for 1, 3 or
7 days. Cultured cells were incubated with CellTiter 96R Aqueous
Non-Radioactive Cell Proliferation Assay (MTS) according to man-
ufacturer’s instructions (Promega; no. G5421). Absorbance was
recorded at 490 nm (Bio-Tek Powerwave HT Microplate Reader).
Each assay was repeated with six technical replicates and three
biological replicates.
2.5. Trypan blue stain
BCL1 cells were trypsinized in 1 ml trypsin (Sigma); cells were
re-suspended in BCL1 media. An equal amount of cell suspen-
sion and trypan-blue solution (Sigma) were mixed together. Cells
were visualized under light microscopy. Five different squares from
a hemocytometer grid were counted to determine the total cell
number and number of dead cells (stained blue). Each assay was
repeated with three technical replicates and three biological repli-
cates.
2.6. Caspase-3/7 assay
BCL1 cells were plated in triplicate at a density of 1 × 105 cells
per well in 96-well plate. After 24 h, cells were transfected with
Zfp521 shRNA or control plasmids as described. Caspase activ-
ity was assessed using Apo-ONE Homogenous Caspase-3/7 Assay
(Promega; no: G7792) according to the manufacturer’s instruc-
tions. Absorbance was recorded at 490 nm.  Wells with no cells
were used a blank, and the average absorbance value of the blank
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Fig. 2. Expression of B-cell genes in Zfp521 knock-down cells. A. The expression of early B-cell genes was assayed by qPCR at 24 and 48 h post-transfection in BCL1 cells
transfected with Zfp521 shRNA or scrambled control plasmid. B. The expression of the recombination gene Rag1 in scrambled control or Zfp521 shRNA transfections. C.
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ransfected with scrambled plasmid for all genes reported in Panel D (*p < 0.05; t te
as subtracted from the average absorbance value for each treat-
ent condition. Fold change for each experimental condition was
alculated by normalization to mock-transfected cells. Each assay
as repeated with three technical replicates and three biological
eplicates.
.7. Real-time quantitative PCR analysis
Total RNA was extracted with TRI reagent (Sigma), treated with
NaseI (Promega), reverse transcribed using random primers and
repared for real-time quantitative PCR (Promega GoTaq qPCR mix)
ccording to manufacturer’s instructions. Primer sequences are
isted in Supplemental Table 1. Reactions were performed in tripli-
ate. Thermal cycling parameters were: 95 ◦C for 10 min, 40 cycles
f 95
◦
C for 15 s, and 60
◦
C for 1 min. Expression levels were normal-
zed to 18S RNA. Expression was analysed using the CT method
13]. Results were analyzed by t test for statistical signiﬁcance.
.8. Site-directed mutagenesis
Site-directed mutagenesis primers were designed using soft-
are from New England BioLabs (http://www.neb.com/products/
0554-q5-site-directed-mutagenesis-kit). The Q5 site-directed
utagenesis kit (New England BioLabs; E0554S) was used follow-ng manufacturer’s instructions to create a stop codon within the
fp521 sequence.
Forward primer: 5′-TGCACAGCTGAGACAGCTGCC-3′
Reverse primer: 5′-CAGCGTCCTCCTCCAACTC-3′ was  signiﬁcantly reduced in Zfp521 shRNA transfected cells as compared to cells
l panels show expression normalized to 18S RNA control.
2.9. Rescue assay
BCL1 cells were plated in 24-well plates at a density of 1.0 × 106
cells per well. Cells were transfected with Zfp521 shRNA plasmid
or control plasmids. The plates were incubated for 3 days, after
which cells were transfected again with the plasmids listed below.
An identical replicate control plate was  mock-transfected without
any addition of any plasmids. Plasmids transfected into knockdown
cells: full-length Zfp521,  mutant Zfp521,  Zfp521Stop, Pax5 wild
type, Pax5 V26G, Ebf1, and cyclin D1.  Following the rescue transfec-
tion cells were subjected to the viability assay described above. The
ratio of viable cells at day 7 post-transfection for rescued cells to
cells without rescue was calculated for each transfection condition.
A pairwise t test was  performed to assess statistical signiﬁcance.
3. Results
3.1. Generation of a Zfp521 B-cell knockdown system
The majority of tumors found in AKXD-27 mice with over-
expression of Zfp521 were of the B-lineage, at the Pro-B cell stage
of differentiation [8]. Zfp521 expression has been reported in wild
type mouse B-cells during early stages of B-cell differentiation [14],
and we  have detected Zfp521 expression in the IL-3 dependent
murine pro-B-cell line Ba/F3 [15] (Fig. 1A), as well as in the mouse
lymphoblast cell line BCL1 (Fig. 1B). To investigate the effects of
reduced Zfp521 expression in B-cells, BCL1 cells were transfected
with either a cocktail of four Zfp521 shRNA knockdown plasmids,
a gene-speciﬁc scrambled control plasmid (scrambled Zfp521 tar-
get sequence), or an empty vector control. Mock-transfected cell
were also analyzed as a further negative control. Zfp521 expression
was assayed by qPCR in BCL1 cells 24 h and 48 h post-transfection.
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Fig. 3. Viability and apoptosis levels in rescue assay cell cultures. A. The ratio of cell viability measured on day 7 post-transfection for cells with Zfp521 wild type rescue
plasmid added (day 7 + ) to cells without rescue plasmid added (day 7). A signiﬁcant increase in viability was found in shRNA cells with Zfp521 wild type rescue plasmid added
as  compared to mock-transfected cells with rescue (*p < 0.05; t test). B. The fold-change in Caspase 3/7 activity in each condition as compared to mock-transfected cells. Cells
without  rescue are shown on the left, and cells with rescue plasmid added are shown in the right. A signiﬁcant different was  found between caspase activity levels in cells
without Zfp521 rescue plasmid transfection to cells with rescue (*p < 0.05; t test). C. The ratio of cell viability measured on day 7 post-transfection for cells with Zfp521
plasmid added. No signiﬁcant difference was  detected in shRNA cells with Zfp521 plasmid added as compared to mock-transfected cells (p = 0.67; t test). D. The ratio of cell
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s  compared to mock-transfected cells (p = 0.15; t test). For all panels, the original t
here was a signiﬁcant decrease in Zfp521 expression in cells trans-
ected with the knockdown plasmid cocktail as compared to cells
ransfected with the scrambled control plasmid at both 24 and 48 h
ost-transfection (Fig. 1B). We  sought to conﬁrm that our BCL1 cells
emonstrated a speciﬁc knockdown of Zfp521 without affecting
xpression of its paralog Zfp423; therefore we measured the expres-
ion levels of Zfp423 in cells transfected with Zfp521 shRNA or the
crambled control plasmid. We  found no difference in the expres-
ion levels of Zfp423 in cells with Zfp521 knockdown as compared to
ontrol plasmid transfected cells, conﬁrming that the knockdown
s speciﬁc to Zfp521 (Fig. 1C).
.2. Zfp521 knockdown cell phenotype
We  employed an enzymatic cell viability assay to determine the
umber of live cells in our different transfection conditions. We
ound that Zfp521 knockdown cells had reduced viability as com-
ared to other transfection conditions, with a signiﬁcant decrease
n cell viability by day 7 post-transfection (Fig. 1D). To conﬁrm these
ndings, trypan blue staining was used to identify dead cells in
ach transfection condition. The percentage of dead cells was  sig-
iﬁcantly increased in the Zfp521 knockdown transfection cells as
ompared to control transfection samples (Fig. 1E).Because we detected reduced cell viability in Zfp521 knockdown
ells, we sought to determine if the reduced viability was due to
ncreased apoptosis. We measured caspase-3/7 activity at 24 h, 3
ays, and 7 days post-transfection in Zfp521 knockdown and con- signiﬁcant difference was detected in shRNA cells with Zfp521Stop plasmid added
ction condition is shown in the legend.
trol plasmid transfected cells. The fold change in levels of apoptotic
cells was  increased in cells transfected with the Zfp521 shRNA plas-
mid  cocktail as compared to mock transfection conditions, with a
signiﬁcant difference detected at day 7 post-transfection (Fig. 1F).
3.3. B-cell gene expression analysis
To determine the effect of the knockdown of Zfp521 on genes
required for B-cell differentiation, we examined gene expression
using quantitative RT-PCR in cells with Zfp521 knockdown as com-
pared to control transfected cells. We  analyzed the expression of
B-cell transcription factors required prior to the Pro-B-cell stage
of differentiation: Ikaros and Ebf1 [4]. Ikaros plays a critical role
in regulating lymphocyte development, function, and homeostasis
[16]. Early B-cell factor (EBF) is a transcription factor involved in the
transcriptional regulation of many B-cell restricted genes, which is
essential for B lymphocyte development [17]. There was no reduc-
tion in the expression of either gene in Zfp521 knockdown cells
(Fig. 2A). Rag1 and Rag2 are lymphocyte-speciﬁc genes involved
in V(D)J rearrangement of immunoglobulin (Ig) [18],  which are
expressed in early lymphoid progenitors [19]. No difference was
observed in the expression of Rag1 in cells with Zfp521 knockdown
as compared to control-transfected cells (Fig. 2B). We  analyzed the
expression of genes acting at later stages of B-cell differentiation:
Pax5, Runx1,  E2F2, and Lrf.  Pax5 is expressed from early pro-B stage
until the ﬁnal stage of differentiation [20], and functions at the Pro-
B-cell stage to activate genes crucial to B-cell lineage differentiation
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Fig. 4. Cell viability measurements in rescue assays. A. The ratio of viable cells detected in cultures at day 7 post-transfection with wild type Pax5 rescue plasmid (7+)
compared to cells mock transfected on day 7. A signiﬁcant increase in viable cell number is seen in cells originally transfected with Zfp521 shRNA when compared to other
transfection conditions (*p < 0.05; t test). B. The ratio of viable cells at day 7 post-transfection with Pax5 V26G mutant construct compared to cells without rescue. No
signiﬁcant differences were detected between any transfection groups. C. The ratio of viable cells in rescue assays with the addition of cyclin D1 plasmid as compared to
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*p  < 0.05; t test). D. The ratio of viable cells at day 7 post-transfection with Ebf1 plas
ny  transfection groups. For all panels, the original transfection condition is shown
nd repress genes required for commitment to other hematopoi-
tic lineages [21]. Runx1 is expressed in early B-cell progenitor and
n immature and mature B-cells [22]. Mice with deletions of E2F1
nd E2F2 have inhibited B-cell differentiation, with development
rrested at the pre-BII stage, indicating a requirement for E2F2 at
he Large Pre-BII to Small Pre-BII differentiation transition [23]. Lrf
egulates the lineage fate of mature B cells, and is highly expressed
n lymphoma cell lines [24]. We  found reduced Pax5, Runx1,  E2F2,
nd Lrf gene expression levels in Zfp521 knockdown cells as com-
ared to controls (Fig. 2C).
.4. Zfp521 knockdown rescue assay
To conﬁrm that the reduced cell viability and increased apo-
tosis we saw in BCL1 knockdown cells was due to a loss of Zfp521
xpression, we developed a rescue assay system in these cells. Cells
ere transfected with the Zfp521 knockdown shRNA cocktail or
ontrol plasmids as described above. On day 3 after the shRNA
ransfection, cells were transfected with a rescue construct. Cell
iability was measured on day 7 after the rescue transfection. The
atio of viable cell number between cells receiving the rescue plas-
id  (denoted 7 + ) compared to control cells receiving no rescue
lasmid (denoted 7) was calculated. We  found that the addition of
ild type Zfp521 resulted in a rescue of cell viability in cells orig-
nally transfected with the Zfp521 shRNA (Fig. 3A). The presence
f caspase 3/7 activity was also measured at day 7 after the recue
ransfection. Cells that were not transfected with the Zfp521 res-
ue plasmid showed a signiﬁcant increase in apoptosis following
fp521 knockdown, however no such increase was  noted in cells
ith Zfp521 rescue transfection (Fig. 3B).y transfected with Zfp521 shRNA when compared to other transfection conditions
ompared to cells without rescue. No signiﬁcant differences were detected between
 legend.
Prior studies have shown that the ﬁnal 4 zinc ﬁngers of
Zfp521 are required for protein-protein interactions with the B-cell
transcription factor EBF1 [25]. A mammalian expression con-
struct lacking the ﬁnal 6 zinc ﬁngers of Zfp521 has previously
been demonstrated to modulate EBF1 activity [8]. This construct
(Zfp521) did not rescue cell viability in cells transfected with
the Zfp521 shRNA (Fig. 3C). The Zfp521 construct was  generated
through an internal restriction enzyme deletion of the wild type
Zfp521 expression plasmid, and therfore has a reduced nucleotide
length compared to the wild type Zfp521 expression plasmid. To
conﬁrm that the lack of rescue in Zfp521 knockdown cells was
not an artifact of the Zfp521 construct, we generated another
mutant Zfp521 expression construct through site-directed muta-
genesis. This new construct (Zfp521Stop) is the same as the wild
type Zfp521 plasmid with the exception of a single nucleotide sub-
stitution that generates a premature stop codon at amino acid 58
of Zfp521. The Zfp521Stop construct was also unable to rescue cell
viability in our assay (Fig. 3D).
3.5. Zfp521 target gene rescue assay
We  used our rescue assay system to examine potential down-
stream targets of Zfp521. We examined Pax5 because Pax5
expression levels are increased in lymphoid tumors from mice with
retroviral insertions at the Evi3 site [8], supporting the hypothesis
that Pax5 is downstream of Zfp521.  To control for changes in viable
cell number caused by general proliferative actions of the rescue
candidates, we calculated the ratio of increase in viable cell num-
ber on day 7 for cells in each knockdown condition receiving the
rescue plasmid (day 7 + ) as compared to cells without the addi-
S. Al Dallal et al. / Leukemia Research 46 (2016) 10–17 15
Fig. 5. Expression analysis in AKXD27 tumors and leukemia cell lines. A. cyclin D1 expression measured by qPCR in tumors from mice with retroviral insertions at Evi3
(27-222  and 27-172) is increased as compared to a control tumor (27-165). B. Zfp521 expression levels in the same AKXD27 tumors. C. cyclin D1 expression levels in leukemia
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ost-transfection. A decrease in cyclin D1 expression is shown in Zfp521 shRNA tran
ion of rescue plasmid (day 7). We  found that the addition of wild
ype Pax5 resulted in a signiﬁcant increase in cell viability in Zfp521
nockdown cells (Fig. 4A). To determine whether the DNA binding
unction of Pax5 was required for rescue, a construct containing
 V26G mutation in Pax5 that lacks DNA binding ability was  used
26]. The addition of mutant Pax5 showed no increase in viability
f Zfp521 knockdown cells (Fig. 4B).
Notably, cyclin D1 has been identiﬁed as an indirect target of
fp521 in chondrocytes, and depletion of Zfp521 in chondrocytes
esults in reduced cell proliferation [27]. We  wished to examine
hether the cell proliferation defects observed in Zfp521 knock-
own cells might therefore be a consequence of perturbed cyclin
1 activity. Our rescue assay conﬁrmed that the addition of cyclin
1 rescued cell viability speciﬁcally in the Zfp521 knockdown cells
Fig. 4C), suggesting that loss of Zfp521 disrupts cyclin D1 regulation
n B-cells.
The B-cell transcription factor Ebf1 was found to be over-
xpressed in tumors with Zfp521 retroviral insertions [8], and is a
utative binding partner for Zfp521 [28,29]. Yet in our knockdown
ssay we found no signiﬁcant alterations in Ebf1 expression lev-
ls. To further delineate the relationship between Ebf1 and Zfp521
e examined whether the introduction of Ebf1 expression would
ffect Zfp521 knockdown cell viability in our rescue assay. However,
he addition of Ebf1 did not rescue cell viability defects (Fig. 4D),
onsistent with the ﬁnding that Ebf1 expression is not altered by
he knockdown of Zfp521.  This ﬁnding suggests that Ebf1 is not a
ownstream target of Zfp521..6. AKXD27 tumor expression analysis
Based on the ﬁnding that cyclin D1 rescued cell viability in Zfp521
nockdown cells, we examined whether AKXD27 B-cell tumorsniﬁcant increase in cyclin D1 expression as compared to BCL1 cells transfected with
 cells transfected with either the Zfp521 shRNA or scrambled shRNA at 24 and 48 h
ns compared to cells transfected with scrambled shRNA sequence (*p < 0.1; t test).
had perturbed expression of cyclin D1.  We found that cyclin D1
expression is up regulated in tumors from AKXD27 mice with retro-
viral insertions at Evi3 as compared to a control tumor without an
Evi3 retroviral insertion (Fig. 5A). Zfp521 over-expression is also
detected in the tumors with retroviral insertions at the Evi3 locus
(Fig. 5B). Furthermore, cyclin D1 expression is increased in a B-
cell leukemia cell line (NSF-467) with a retroviral insertion at the
Evi3 locus, when compared to B-cell lines without Evi3 retroviral
insertions (Fig. 5C). We  also conﬁrmed that cyclin D1 expression is
reduced in cells with Zfp521 knockdown compared to control cells,
indicating that cyclin D1 is downstream of Zfp521 in B-cells (Fig. 5D).
4. Discussion
Zfp521 encodes a transcription factor with an N-terminal tran-
scriptional repressor motif [30] and 30 Kruppel-like-zinc ﬁnger
domains [8,9]. Due to the increased numbers of B-cells in mice
with Zfp521 over-expression, we  postulated that Zfp521 may  func-
tion during B-cell development to regulate B-cell viability or
proliferation. Additionally, the ﬁnding that mice with Zfp521 over-
expression have an inappropriate B-cell surface marker proﬁle,
with upregulation of markers expressed from the pro-B stage of dif-
ferentiation [8], raises the possibility that Zfp521 functions as part
of the B-cell transcription factor network to promote differentiation
events.
The results from our Zfp521 knockdown culture system are con-
sistent with the above hypotheses. We  discovered that BCL1 cell
viability is reduced and apoptosis is signiﬁcantly increased when
Zfp521 is knocked down, suggesting a role for Zfp521 in B-cell sur-
vival. Our results support a role for Zfp521 in the regulation of genes
expressed from the Pro-B-stage onwards. These results are consis-
tent with the ﬁndings from a recent study reporting a role for Zfp521
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n regulation of the pre-B-cell receptor genes BTK, BANK1, and BLNK
14]. Moderate levels of ZNF521 expression have also been noted in
he human Raji (pre-B) cell line [10].
Retroviral insertion at the Evi3 locus causing Zfp521 over-
xpression is a cooperative event in the development of acute
-lineage leukemia in mice expressing an E2A-HLF chimeric pro-
ein associated with acute lymphoblastic leukemia t(17;19) [31].
he tumors in these mice are of the B-progenitor type, and express
220 and Cd19, similar to tumors found in AKXD27 mice with
etroviral insertions at the Evi3 locus [8]. Further studies revealed
NF521 overexpression in human leukemic cell lines with t(17;19)
ranslocations [31], suggesting that the mechanism by which
ver-expression of Zfp521/ZNF521 causes B-cell leukemia may  be
onserved between mouse and human. Transgenic mice that over-
xpress both the E2A-HLF fusion gene and Zfp521 showed increased
roliferation of B-cell progenitors [31]. Our study suggests that the
ncreased proliferation found in Zpf521 over-expressing Pro-B-cells
s mediated by cyclin D1.  Additionally, Zfp521 has been reported to
egulate cyclin D3 expression in Pre-B-cells [14], suggesting that
erturbations of Zfp521 expression disrupt the G1/S transition in
he cell cycle.
The knockdown of Zfp521 in cultured hematopoietic progen-
tor cells has been reported to increase B-cell differentiation, as
ell as increase overall cell number in the culture [30]. The B-cell
enes Ebf1, Pax5, and Mb1  were also up-regulated in these knock-
own cultures [30]. It is possible that knocking down Zfp521 at the
ro-B-cell stage has an opposite effect to its knockdown in progen-
tor cells. Knockdown of Zfp521 at the Pre-B-cell stage also reduces
ell proliferation [14], similar to our ﬁndings at the Pro-B-cell
tage. Notably, in Pro-B-cell tumours with Evi3 retroviral insertions,
fp521 over-expression occurs concomittantly with Ebf1, Pax5, and
b1  over-expression, suggesting that Zfp521 has a positive effect
n the transcription of these B-cell factors at the Pro-B-cell stage
8]. We  therefore propose that Zfp521 functions within the B-cell
ranscriptional network to promote differentiation events subse-
uent to the Pro-B-cell stage of lineage commitment. Further study
s needed to determine how perturbations of Zfp521 function at
ifferent stages of B-cell development disrupt the balance of gene
xpression patterns and cellular activities to culminate in leukemic
ransformation of B-lineage cells.
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